항체약물접합체 수탁제조 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Antibody Drug Conjugates Contract Manufacturing Market size is expected to reach USD 27.45 Billion in 2034 from USD 10.37 Billion (2025) growing at a CAGR of 11.42% during 2026-2034.

The Global Antibody Drug Conjugates Contract Manufacturing Market is expanding rapidly as ADCs emerge as a transformative oncology treatment modality. Pharmaceutical companies are increasingly outsourcing complex manufacturing processes involving monoclonal antibodies, cytotoxic payloads, and linker technologies. The technical intricacies and high capital requirements associated with ADC production have strengthened the role of specialized contract manufacturers worldwide.

Growth is primarily driven by the expanding oncology pipeline, rising cancer prevalence, and increasing regulatory approvals for ADC therapies. Advances in conjugation technologies and targeted drug delivery mechanisms have improved therapeutic efficacy and safety profiles. Additionally, biopharma firms are seeking flexible production models to manage clinical-to-commercial scale transitions efficiently, creating strong demand for integrated CDMO services.

Future prospects remain highly promising as next-generation ADCs target broader indications beyond oncology. Continuous investments in high-containment facilities and advanced bioprocessing capabilities will support market expansion. Strategic collaborations and mergers are expected to enhance service portfolios, ensuring the ADC contract manufacturing sector remains a critical backbone of precision medicine innovation.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Condition

• Myeloma
• Lymphoma
• Breast Cancer
• Others

By Linker

• Cleavable Linker
• Non-cleavable Linker

COMPANIES PROFILED

• Sterling, Recipharm AB, Lonza, Catalent Inc, Sartorius AG, Wuxi Biologics, Samsung Biologics, Piramal Group Piramal Pharma Solutions, AbbVie Inc AbbVie Contract Manufacturing, Merck KGaA
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET: BY CONDITION 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Condition
• 4.2. Myeloma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Lymphoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET: BY LINKER 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Linker
• 5.2. Cleavable Linker Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Non-cleavable Linker Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Condition
  • 6.2.2 By Linker
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Condition
  • 6.3.2 By Linker
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Condition
  • 6.4.2 By Linker
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Condition
  • 6.5.2 By Linker
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Condition
  • 6.6.2 By Linker
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 Sterling
  • 8.2.2 Recipharm AB
  • 8.2.3 Lonza
  • 8.2.4 Catalent Inc
  • 8.2.5 Sartorius AG
  • 8.2.6 Wuxi Biologics
  • 8.2.7 Samsung Biologics
  • 8.2.8 Piramal Group (Piramal Pharma Solutions)
  • 8.2.9 AbbVie Inc. (AbbVie Contract Manufacturing)
  • 8.2.10 Merck KGaA